CoMparison of TriflusAl and Clopidogrel Effect in Secondary Prevention of STroke Based on the CytochRome P450 2C19 GenOtyping; MAESTRO study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0000025

Enrollment

1080

Registered

2010-08-25

Start date

2010-03-23

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Genetic : Triflusal (Disgren Capsule), twice a day, 300mg/once, oral, taking the drug during or after a meal, taking period: from randomization to 31 December 2013

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have non-caridogenic ischemic stroke of TOAST classification within 30 days prior to screening 2. = 20 years of age; adult, at the date of signing the informed consent 3. Written informed consent

Exclusion criteria

Exclusion criteria: 1. History for bleeding tendency or recent major bleeding within 2 weeks 2. Chronic liver disease (ALT>100 or AST>100) or renal dysfunction (creatinine>4.0mg/dl) 3. Thrombocytopenia (platelet<100,000mm3) 4. Any contraindication of antiplatelet agent 5. Severe congestive heart failure 6. Patients who need to take anticoagulants or two more antiplatelet agents 7. Severe concomitant disease with the expected survival less than 2 years 8. Pregnant or nursing 9. Any drug clinical trials within 30 days of signing the informed consent

Design outcomes

Primary

Measure	Time frame
Time to first recurrent stroke	—

Secondary

Measure	Time frame
Time to first of MI or coronary artery revascularization;Time to first recurrent ischemic stroke;Time to first of composite cardiovascular events	—

Countries

Korea, Republic of

Contacts

Public ContactKyung-Yul Lee

Yonsei University Health System, Gangnam Severance Hospital

Outcome results